Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 78 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Keyword is Non-alcoholic Fatty Liver Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Polyzos, S. A., Kountouras J., Papatheodorou A., Katsiki E., Patsiaoura K., Zafeiriadou E., et al. (2013).  Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.. Ann Hepatol. 12(5), 749-57.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2016).  Adipokines in nonalcoholic fatty liver disease.. Metabolism. 65(8), 1062-79.
Polyzos, S. A., & Mantzoros C. S. (2016).  Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review.. Metabolism. 65(9), 1297-306.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2017).  Adipose tissue, obesity and non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 92-108.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  Are statins 'IDEAL' for non-alcoholic fatty liver disease?. Curr Med Res Opin. 30(2), 229-31.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Margouta A., & Mantzoros C. S. (2015).  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.. Endocrine. 49(2), 560-2.
C
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Cardiovascular benefits of bariatric surgery in morbidly obese patients.. Obes Rev. 12(7), 515-24.
Athyros, V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2015).  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World J Gastroenterol. 21(22), 6820-34.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Savvidou, S., Karatzidou K., Tsakiri K., Gagalis A., Hytiroglou P., & Goulis J. (2016).  Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.. Diabetes Res Clin Pract. 113, 125-34.
Polyzos, S. A., Kountouras J., & Tsoukas M. A. (2015).  Circulating homocysteine in nonalcoholic fatty liver disease.. Eur J Intern Med. 26(2), 152-3.
Polyzos, S. A., Aronis K. N., Kountouras J., Raptis D. D., Vasiloglou M. F., & Mantzoros C. S. (2016).  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.. Diabetologia. 59(1), 30-43.
Polyzos, S. A., Anastasilakis A. D., Kountouras J., Makras P., Papatheodorou A., Kokkoris P., et al. (2016).  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.. J Bone Miner Metab. 34(4), 447-56.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Malandris, K., Papandreou S., Avgerinos I., Karagiannis T., Paschos P., Michailidis T., et al. (2023).  Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis.. Hormones (Athens). 22(4), 655-664.
Lazaridis, N., & Tsochatzis E. (2017).  Current and future treatment options in non-alcoholic steatohepatitis (NASH).. Expert Rev Gastroenterol Hepatol. 11(4), 357-369.
E
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Polyzos, S. A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., & Kountouras J. (2014).  Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.. Arq Gastroenterol. 51(3), 261-8.
Mitsiou, E., Boutari C., Kotsis V., Georgianou E., Doumas M., Karagiannis A., et al. (2018).  Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.. Curr Vasc Pharmacol. 16(4), 393-400.
Kargiotis, K., Katsiki N., Athyros V. G., Giouleme O., Patsiaoura K., Katsiki E., et al. (2014).  Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.. Curr Vasc Pharmacol. 12(3), 505-11.
Polyzos, S. A., Kountouras J., Zafeiriadou E., Patsiaoura K., Katsiki E., Deretzi G., et al. (2011).  Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.. J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
Polyzos, S. A., Kountouras J., Mantzoros C. S., Polymerou V., & Katsinelos P. (2017).  Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.. Diabetes Obes Metab. 19(12), 1805-1809.
Mintziori, G., & Polyzos S. A. (2016).  Emerging and future therapies for nonalcoholic steatohepatitis in adults.. Expert Opin Pharmacother. 17(14), 1937-46.
Polyzos, S. A., Kountouras J., Deretzi G., Zavos C., & Mantzoros C. S. (2012).  The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.. Curr Mol Med. 12(1), 68-82.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές